R. John Stubbs, Ph.D.
John Stubbs has over 35 years of experience in Pharmaceutical R&D, primarily in bioanalytical chemistry, analytical chemistry, drug metabolism, and all phases of drug development. He holds a BS in Chemistry from the University of Salford, and a Ph.D. in Bioanalytical Chemistry and Drug Metabolism from the School of Pharmacy, University of London.
John began his pharmaceutical career with Beecham and Merck Research Labs in the UK, and transferred to the USA with Merck Research Labs working in drug metabolism. He worked in R&D for Johnson & Johnson holding various positions of increasing responsibility, and his last role was global head of bioanalytical supporting preclinical, clinical pharmacokinetics and toxicology Departments, using HPLC, LC-MS/MS, CE, and immunochemistry technology. He also spent almost 4 years in the Quality and Compliance group, heading up stability testing, lab investigations, new methods, and lab IT groups.
John has been an active member of AAPS and ISSX, and was a past member of the PhRMA Drug Metabolism Steering Committee. He is a founding member, and served on the Land O’Lakes drug metabolism/applied pharmacokinetics and analytical planning committees, and is also a member of the planning committee for the bioanalytical conference. He has given many presentations and published widely, primarily in the fields of bioanalytical chemistry and drug metabolism.
John began his pharmaceutical career with Beecham and Merck Research Labs in the UK, and transferred to the USA with Merck Research Labs working in drug metabolism. He worked in R&D for Johnson & Johnson holding various positions of increasing responsibility, and his last role was global head of bioanalytical supporting preclinical, clinical pharmacokinetics and toxicology Departments, using HPLC, LC-MS/MS, CE, and immunochemistry technology. He also spent almost 4 years in the Quality and Compliance group, heading up stability testing, lab investigations, new methods, and lab IT groups.
John has been an active member of AAPS and ISSX, and was a past member of the PhRMA Drug Metabolism Steering Committee. He is a founding member, and served on the Land O’Lakes drug metabolism/applied pharmacokinetics and analytical planning committees, and is also a member of the planning committee for the bioanalytical conference. He has given many presentations and published widely, primarily in the fields of bioanalytical chemistry and drug metabolism.